ClinicalTrials.Veeva

Menu

Volume Kinetics for 20% Albumin in Different Clinical Situations

S

Sodertalje Hospital

Status and phase

Unknown
Phase 4

Conditions

Inflammation
Unconscious

Treatments

Drug: Albumin 20%

Study type

Interventional

Funder types

Other

Identifiers

NCT02556580
Albumin April 2015

Details and patient eligibility

About

The study aims to determine the degree of plasma volume expansion and the half-life of the plasma volume expansion when 3 mL/kg of hyperoncotic (20%) albumin if infused over 30 minutes in conscious healthy volunteers, in patients undergoing surgery under general anesthesia, and on the day after major surgery when the patient is in a post surgical inflammatory state. The study also examines the increase in the plasma colloid osmotic pressure as a result of this infusion and its possible influence on markers of kidney damage.

Full description

15 volunteers, 15 patients undergoing surgery and 15 patients in the post-surgical phase will be recruited for this study because they have different degrees of vasodilatation and inflammation, which are factors of potential importance to the effectiveness of plasma volume expansion with albumin 20%. Hyperoncotic albumin should logically recruit fluid from the interstitial fluid space, but this possibility has recently been questioned in the "revised Starling equation".

The degree of plasma volume expansion and also the half-life will be estimated by population volume kinetics which uses serial analyses of the blood hemoglobin concentration and a summary measure of the excreted urine during the 5-hour experiment to calculate these outcome measures.

There is a risk that hyperoncotic solutions cause pre-renal anuria due to the rise in plasma oncotic pressure. As a safety measure we will assess the plasma oncotic pressure and relevant biomarkers of renal function during the experiments. The experiments will be ended with a slow infusion of 1 L of Ringer´s acetate to dilute any raised oncotic pressure.

Enrollment

45 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy volunteers.
  • Patients in ASA classes I-II scheduled for surgery.

Exclusion criteria

  • Expected major hemorrhage during surgery.
  • Blood hemoglobin concentration of < 10 g/dL.

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

45 participants in 3 patient groups

Conscious healthy volunteers
Active Comparator group
Description:
Intervention: intravenious infusion Drug: albumin 20%
Treatment:
Drug: Albumin 20%
Surgery under general anesthesia
Experimental group
Description:
Intervention: intravenious infusion Drug: albumin 20%
Treatment:
Drug: Albumin 20%
Post-surgical inflammation
Experimental group
Description:
Intervention: intravenious infusion Drug: albumin 20%
Treatment:
Drug: Albumin 20%

Trial contacts and locations

2

Loading...

Central trial contact

Robert G Hahn, MD, PhD; Joachim Zdolsek, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems